Incidence of neutropenia during administration of study drug and during the 100-day posttransplantation period
| Patient absolute neutrophil levels, no. (%) . | Placebo, n = 28 . | Maribavir dose groups . | ||
|---|---|---|---|---|
| 100 mg twice daily, n = 28 . | 400 mg once daily, n = 28 . | 400 mg twice daily, n = 26* . | ||
| While taking study drug | ||||
| Less than 1000/mm3 | 4 (14) | 6 (21) | 5 (18) | 4 (15) |
| Less than 750/mm3 | 4 (14) | 4 (14) | 3 (11) | 3 (12) |
| Less than 500/mm3 | 2 (7) | 3 (11) | 2 (7) | 1 (4) |
| During the 100-day posttransplantation period | ||||
| Less than 1000/mm3 | 11 (39) | 7 (25) | 6 (21) | 9 (35) |
| Less than 750/mm3 | 11 (39) | 4 (14) | 5 (18) | 7 (27) |
| Less than 500/mm3 | 6 (21) | 3 (11) | 3 (11) | 3 (12) |
| Patient absolute neutrophil levels, no. (%) . | Placebo, n = 28 . | Maribavir dose groups . | ||
|---|---|---|---|---|
| 100 mg twice daily, n = 28 . | 400 mg once daily, n = 28 . | 400 mg twice daily, n = 26* . | ||
| While taking study drug | ||||
| Less than 1000/mm3 | 4 (14) | 6 (21) | 5 (18) | 4 (15) |
| Less than 750/mm3 | 4 (14) | 4 (14) | 3 (11) | 3 (12) |
| Less than 500/mm3 | 2 (7) | 3 (11) | 2 (7) | 1 (4) |
| During the 100-day posttransplantation period | ||||
| Less than 1000/mm3 | 11 (39) | 7 (25) | 6 (21) | 9 (35) |
| Less than 750/mm3 | 11 (39) | 4 (14) | 5 (18) | 7 (27) |
| Less than 500/mm3 | 6 (21) | 3 (11) | 3 (11) | 3 (12) |
One patient randomized to maribavir 400 mg twice daily did not receive study drug and was excluded from the analysis.